<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325308</url>
  </required_header>
  <id_info>
    <org_study_id>300005089</org_study_id>
    <nct_id>NCT04325308</nct_id>
  </id_info>
  <brief_title>Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk</brief_title>
  <official_title>Early Life Protein-enriched Human Milk Diets to Increase Lean Body Mass Accretion and Diversity of the Gut Microbiome in Extremely Preterm Infants: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central hypothesis of this clinical trial is that, in extremely preterm infants,
      protein-enriched human milk diets compared to usual human milk diets during the first 2 weeks
      after birth increase fat-free mass (FFM)-for-age Z scores and promote maturation of the gut
      microbiome at term corrected age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Masked randomized clinical trial in which extremely preterm infants fed human milk will be
      randomly assigned to receive either a protein-enriched diet (intervention group) or a usual
      diet (control group) within the first 96 hours after birth.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Caregivers and primary outcome evaluators will be masked. Nutrition room staff not involved in patient care will be responsible for determining participant allocation to one of the supplementation groups by opening sequentially numbered sealed envelopes, dispensing feeding syringes with the allocated human milk diet (protein-enriched or usual), and masking caregivers administering the assigned dietary intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fat-free mass(FFM)-for-age Z-score</measure>
    <time_frame>36 weeks or hospital discharge</time_frame>
    <description>FFM accretion will be estimated by air displacement plethysmography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fat mass(FM)-for-age Z-score</measure>
    <time_frame>36 weeks or hospital discharge</time_frame>
    <description>FM accretion will be estimated by air displacement plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat(BF)-for-age Z-score</measure>
    <time_frame>36 weeks or hospital discharge</time_frame>
    <description>Percent BF will be estimated by air displacement plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurements</measure>
    <time_frame>Birth to 36 weeks postmenstrual age or hospital discharge</time_frame>
    <description>Weight, length, and head circumference measurements at regular intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth rate</measure>
    <time_frame>Birth to 36 weeks postmenstrual age or hospital discharge</time_frame>
    <description>Weight gain in g/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with postnatal growth failure</measure>
    <time_frame>36 weeks or hospital discharge</time_frame>
    <description>Diagnosis of growth failure (weight &lt; 10th percentile)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with diagnosis of necrotizing enterocolitis</measure>
    <time_frame>Birth to 120 days or discharge, whichever occurs first</time_frame>
    <description>Diagnosis of necrotizing enterocolitis stage 2 or 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with diagnosis of intestinal perforation</measure>
    <time_frame>Birth to 120 days or discharge, whichever occurs first</time_frame>
    <description>Diagnosis of intestinal perforation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Birth to 120 days</time_frame>
    <description>Death prior to 121 days of birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Culture-proven sepsis</measure>
    <time_frame>Birth to 120 days</time_frame>
    <description>Diagnosis of sepsis with positive blood cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive and receiving full enteral feeding</measure>
    <time_frame>Birth to 28 days</time_frame>
    <description>Total number of full enteral feeding days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of feeding intolerance</measure>
    <time_frame>Birth to 28 days</time_frame>
    <description>Interruption or cessation of enteral feeds for a period greater than 12 hours for abnormal abdominal examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay in days</measure>
    <time_frame>Birth to 120 days or discharge, whichever occurs first</time_frame>
    <description>From day of admission to day of hospital discharge to home</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in intestinal microbiome</measure>
    <time_frame>Birth to 36 weeks postmenstrual age</time_frame>
    <description>Determined by molecular analyses of fecal samples</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prematurity; Extreme</condition>
  <condition>Feeding Disorder Neonatal</condition>
  <condition>Breast Milk Expression</condition>
  <condition>Growth Failure</condition>
  <condition>Microbial Colonization</condition>
  <arm_group>
    <arm_group_label>Protein-enriched human milk diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants in this group will receive protein-enriched expressed human milk or donor human milk during the first 2 weeks after birth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual human milk diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants in this group will receive either expressed human milk or donor human milk during the first 2 weeks after birth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Protein-enriched human milk diet</intervention_name>
    <description>1.2 g of human-based protein will be added to each 100 ml of human milk administered</description>
    <arm_group_label>Protein-enriched human milk diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Usual human milk diet</intervention_name>
    <description>Human-based protein will not be added to the human milk administered.</description>
    <arm_group_label>Usual human milk diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age â‰¤ 28 weeks of gestation

          -  Postnatal age &lt; 96 hours

        Exclusion Criteria:

          -  Congenital malformations

          -  Chromosomal anomalies

          -  Terminal illness needing to limit or withhold support
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariel Salas, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ariel Salas, MD, MSPH</last_name>
    <phone>205-934-4680</phone>
    <email>asalas@peds.uab.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Ariel A. Salas, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Failure to Thrive</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

